PefloxacinThird Party Manufacturing in India

Pefloxacin is a broad-spectrum fluoroquinolone antibiotic that exhibits potent bactericidal activity against a wide range of Gram-negative and Gram-positive bacteria.

Pefloxacin works by inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase is responsible for introducing negative supercoils into bacterial DNA, a critical step that allows the long circular bacterial chromosome to fit inside the cell. Topoisomerase IV is required for decatenation, the separation of replicated daughter chromosomes during cell division. By binding to these enzyme-DNA complexes, Pefloxacin stabilizes the cleaved DNA strands, preventing religation and leading to double-strand DNA breaks. This triggers bacterial cell death through the accumulation of fragmented DNA.

Pefloxacin has excellent bioavailability and tissue penetration, including effective distribution into the lungs, kidneys, prostate, bone, and soft tissues. Unlike some other fluoroquinolones, Pefloxacin undergoes hepatic metabolism with enterohepatic circulation, contributing to its prolonged half-life and sustained therapeutic effect. It is particularly active against Enterobacteriaceae, Staphylococcus species, Pseudomonas aeruginosa, and other clinically significant Gram-negative pathogens.

Pefloxacin is distinguished from earlier quinolones by its enhanced activity against Gram-positive organisms and atypical pathogens such as Mycoplasma and Chlamydia, making it valuable for empiric therapy in a variety of infections.

Therapeutic Uses

Pefloxacin IV infusion is prescribed for the treatment of serious bacterial infections:

• Urinary Tract Infections: Complicated UTIs, pyelonephritis, and prostatitis caused by Enterobacteriaceae and Pseudomonas species.
• Respiratory Tract Infections: Hospital-acquired pneumonia, bronchiectasis exacerbations, and chronic obstructive pulmonary disease infections.
• Gastrointestinal Infections: Bacterial gastroenteritis, typhoid fever, and intra-abdominal infections including peritonitis.
• Bone and Joint Infections: Osteomyelitis and septic arthritis where Gram-negative organisms are involved.
• Skin and Soft Tissue Infections: Severe cellulitis, infected ulcers, and post-surgical wound infections.
• Septicemia: Gram-negative bacteremia and sepsis syndrome in hospital settings, especially where Enterobacteriaceae are suspected.

Why Manufacturers Choose Pefloxacin

Pefloxacin infusion 400mg/100ml is a widely prescribed hospital antibiotic, particularly in Indian healthcare settings where its cost-effectiveness and broad-spectrum coverage make it a preferred choice for empiric therapy. The molecule is included in many hospital antibiotic policies and stewardship programs. Indian manufacturers benefit from a well-established API supply base, mature production processes for IV infusions, and strong demand from institutional buyers in India, CIS countries, Africa, and Southeast Asia. The product has consistent year-round demand driven by hospital procurement cycles.

This makes Pefloxacin a reliable product for third party manufacturing in India, with steady demand from institutional buyers, government tenders, and PCD franchise partners.